Merck KGaA, in the middle of a reformation plot in its biopharma division, has found a new head of drug R&D, moving on after its last research chief lasted just 6 months in the job.
Mersana Therapeutics has inked another antibody-drug conjugate development pact, this time with the R&D team at Merck KGaA in Germany.
Merck KGaA is backing out of its multiple sclerosis deal with Japan's Ono Pharmaceutical, deciding not to take the plunge on Phase III development for a drug that would face stiff competition.
MorphoSys has notched another high-profile pharma partnership on its belt of antibody deals, and it's set its sights on immune checkpoint inhibitors. With this pact, Merck KGaA is also staking out a position on the growing roster of companies scrambling to find a profitable place for itself in immuno-oncology.
Merck KGaA has long said it's not affraid to spend big on bolstering its pipeline, and part of the German drugmaker's value-creation plan is a sizable investment in biosimilars.
Rival drugmakers Merck KGaA and Pfizer are putting their cash and expertise into a new effort to better understand lupus, tapping the Broad Institute for a Big Data approach to help map out the disease and light the way for future drug candidates.
Welcome to our first edition of the weekly EuroBiotech Report, where FierceBiotech will go deeper into the news and events happening in Europe.
The execs at Merck KGaA have been hinting around for months now that they're interested in doing some sizable deals to build up the drug R&D side of the business at the conglomerate. And CEO Karl-Ludwig Kley helped feed the rumor mill on Friday with his boast that the company has deep enough pockets to pull off a multibillion-dollar buyout without straining.
For nearly 100 years, Merck and Merck KGaA have been independent entities, but their shared name has led to confusion, sniping and even legal fracas. Now the two former relatives are working behind closed doors to smooth things over, Bloomberg reports, but don't expect either to bend much on the issue of identity.
A series of setbacks has made things tough for Merck KGaA's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the long-term promise of its pharma wing.